No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT
Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Regulatory
Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at GEN — Genetic Engineering & Biotechnology News.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.